NCT05418868 - A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

July 6, 2026

Study Completion Date

November 2, 2027

Conditions

HIV Infections

Interventions

DRUG

Cabotegravir 200 mg/mL

CAB 200 mg/mL will be administered.

DRUG

Cabotegravir >=400 mg/mL

CAB \>=400 mg/mL will be administered by IM or SC injection.

DRUG

Cabotegravir Formulation I

CAB Formulation I will be administered by IM injection.

DRUG

CAB Formulation J

CAB Formulation J will be administered by IM injection.

DRUG

rHuPH20

rHuPH20 will be administered.

DRUG

RPV

RPV will be administered by IM injection.

Trial Locations (3)

COMPLETED

GSK Investigational Site, Orlando

RECRUITING

GSK Investigational Site, Austin

RECRUITING

GSK Investigational Site, Las Vegas